Research Papers:

Serum Helicobacter pylori FliD antibody and the risk of gastric cancer

Hailin Li, Bing Zhang, Xiaomeng Hu, Yingzi Dong, Qing Fan, Fang Guo, Xiyun Ren, Haibo Zhou, Wenjing Tian _ and Yashuang Zhao

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:22397-22408. https://doi.org/10.18632/oncotarget.7981

Metrics: PDF 2325 views  |   HTML 1935 views  |   ?  


Hailin Li1, Bing Zhang1, Xiaomeng Hu1, Yingzi Dong1, Qing Fan2, Fang Guo1, Xiyun Ren1, Haibo Zhou1, Wenjing Tian1, Yashuang Zhao1

1Department of Epidemiology, College of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, P. R. China

2Xiangfang Center for Disease Control and Prevention, Harbin, Heilongjiang Province, P. R. China

Correspondence to:

Wenjing Tian, email: [email protected]

Yashuang, Zhao, email: [email protected]

Keywords: H. pylori FliD protein, H. pylori CagA protein, serum antibody, gastric cancer, case-control study

Received: November 07, 2015     Accepted: February 23, 2016     Published: March 8, 2016


FliD and CagA are important virulence factors of H. pylori. We aimed to evaluate the screening values of FliD and CagA for gastric cancer (GC). Serum samples were obtained from 232 cases and 266 controls in a case-control study. Unconditional multivariate logistic regression with odds ratios (ORs) and 95% confidence intervals (CIs) was used to analyze the relationships between FliD, CagA and GC. The sensitivities, specificities and receiver operating characteristic (ROC) curves were calculated. Finally, the combined screening values of FliD, FlaA, NapA and CagA were assessed based on discriminant analysis. In all subjects, the associations of FliD and CagA with GC were evident with ORs (95% CIs) of 7.6 (4.7-12.3) and 2.5 (1.6-3.8), respectively (*p<0.001). The areas under ROC curves (AUCs) for FliD and CagA were 0.800 and 0.653, respectively. The AUC for the combination of FliD, FlaA and NapA was 0.915, which represented an increase of 0.115 over that of FliD alone (*p<0.001). These findings indicate that the FliD antibody is associated with GC and could exhibit high validity as a biomarker in screening for GC patients. The combination of FliD, FlaA and NapA improved the screening validity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7981